Boston Scientific to Participate in 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

MARLBOROUGH, Mass. /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018 in New York City.

David Pierce, executive vice president and president, MedSurg and Susie Lisa, vice president, Investor Relations, will participate in a 60-minute roundtable discussion session with the host analyst beginning at approximately 9:30 a.m. EST.  A live webcast of the session will be available on the Investor Relations section of the Boston Scientific website at

A replay of the webcast will be accessible at investors.bostonscientific.com approximately one hour following the completion of the event.




Kate Haranis             

Susie Lisa, CFA

508-683-6585 (office)            

508-683-5565 (office)

Media Relations                

Investor Relations

Boston Scientific Corporation        

Boston Scientific Corporation      

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 35 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.